AIM AIM ImmunoTech Inc.

2.15
+0.12  (+6%)
Previous Close 2.03
Open 2
52 Week Low 0.381
52 Week High 7.11
Market Cap $85,333,526
Shares 39,690,012
Float 2,304,903
Enterprise Value $130,562,439
Volume 1,507,395
Av. Daily Volume 5,391,312
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Ampligen plus Intron A
Ovarian cancer
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Ampligen and interferon alpha-2b
COVID-19
Phase 1/2
Phase 1/2
Phase 1/2a trial commencement of recruitment announced September 16, 2020.
Ampligen, Intron A, celecoxib and pembrolizumab
Triple-Negative Breast Cancer
Phase 1
Phase 1
All patients have been treated or are near completion of treatment - August 2020.
Ampligen, Intron A, and celecoxib
Colorectal cancer
Phase 2
Phase 2
Phase 2 trial ongoing.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer
Phase 2
Phase 2
Phase 2 trial is enrolling - noted August 2020.
Ampligen, Intron A
Prostate Cancer
Phase 2
Phase 2
Phase 2 trial has been initiated - noted August 2020.
Ampligen
CFS
CRL
CRL
CRL February 4, 2013.

Latest News

  1. Median survival approximately two-fold higher in Ampligen arm compared to historical controls; AIM to seek FDA Fast Track designation and orphan drug status in late stage pancreatic cancer

    OCALA, FL / ACCESSWIRE / September 22, 2020 / AIM ImmunoTech Inc. (NYSE:AIM) today announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program (EAP) conducted at Erasmus University Medical Center in the Netherlands.

    Prof. Casper van Eijck, MD, PhD, oncologist and a global leading expert in pancreatic cancer

    Prof. Casper van Eijck, MD Ph.D., and his team at Erasmus MC found a statistically significantly positive survival benefit when using Ampligen in patients with locally advanced/metastatic…

    Median survival approximately two-fold higher in Ampligen arm compared to historical controls; AIM to seek FDA Fast Track designation and orphan drug status in late stage pancreatic cancer

    OCALA, FL / ACCESSWIRE / September 22, 2020 / AIM ImmunoTech Inc. (NYSE:AIM) today announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program (EAP) conducted at Erasmus University Medical Center in the Netherlands.

    Prof. Casper van Eijck, MD, PhD, oncologist and a global leading expert in pancreatic cancer

    Prof. Casper van Eijck, MD Ph.D., and his team at Erasmus MC found a statistically significantly positive survival benefit when using Ampligen in patients with locally advanced/metastatic pancreatic cancer after systemic chemotherapy. Prof. van Eijck states, "The overall survival of the experimental group was compared to a large historical control cohort matched for age, gender, stage of disease, and number of cycles of Folfirinox chemotherapy. Median survival was approximately two-fold higher, that is 200%, in the Ampligen arm as compared to the historical controls. These results were obtained with a very high degree of statistical significance. Based on these data, I see the potential for Ampligen as a meaningful extension of the standard of care for advanced pancreatic cancer, which we are planning to investigate further." A detailed clinical report and an article for publication are being prepared by Prof. van Eijck and his team at Erasmus MC.

    AIM CEO Thomas K. Equels states: "We started this program in January 2017. These exceptional results from Erasmus exceed even our most optimistic expectations. I am deeply grateful to Prof. Casper van Eijck, his team at Erasmus, and Ronald Brus, MD, the guiding hand at myTomorrows, for their vision and careful diligence in implementing this important analysis of Ampligen as a single-agent therapy for late-stage pancreatic cancer. I extend deep gratitude to the government of the Netherlands for its pioneering support and commitment to advancing a critical medical innovation in a deadly cancer with very limited medical interventions. Medical advances in lethal unmet medical needs depend on this sort of outstanding clinical and governmental cooperation and support. We could not have accomplished this but for the support of the Netherlands."

    AIM will work with its Contract Research Organization, Amarex Clinical Research LLC, to seek FDA "fast-track" and possibly even FDA "breakthrough" designations and to obtain IND authorizations to conduct a follow-up pancreatic cancer Phase 2/3 clinical trial with sites in the Netherlands at Erasmus MC under Prof. van Eijck, and also at major cancer research centers in the United States. AIM also plans to file dual orphan drug status applications for use of Ampligen in the treatment of late-stage pancreatic carcinoma with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). If granted, this serves to extend a company's exclusivity rights once a drug reaches market.

    About AIM ImmunoTech Inc.
    AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

    Cautionary Statement
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act (PSLRA) of 1995. Words such as "may," "will," "expect," "plan," "anticipate," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the PSLRA. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The statistical analysis of the Erasmus study was based on comparison of the patient group treated with Ampligen to a historical control group of patients with similar characteristics who were previously treated for pancreatic cancer but who did not receive Ampligen. Because these were not concurrent controls, the assignment to treatment with Ampligen was neither randomized nor blinded to the investigators or the patients. Significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of pancreatic cancer in humans, and no assurance can be given that it will be the case. Initiation of future clinical trials may not occur secondary to many factors, including lack of regulatory approval(s) or lack of study drug. Further, there is no assurance that the FDA or EMA will grant an orphan drug designation. In addition, no assurance can be given as to whether future pancreatic immuno-oncology clinical trials will be successful or yield favorable data, and the trials are subject to many factors, including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Additionally, we recognize that all cancer centers, like all medical facilities, must make the ongoing COVID-19 pandemic their priority. Therefore, there is the potential for delays in clinical trial enrollment and reporting in ongoing and future studies in cancer patients because of the COVID-19 medical emergency. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks.

    CONTACT:
    Crescendo Communications, LLC
    Phone: 212-671-1021
    Email:

    AIM ImmunoTech Inc
    Phone: 800-778-4042
    Email:

    SOURCE: AIM ImmunoTech Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/607091/AIM-ImmunoTech-Receives-Statistically-Significant-Positive-Survival-Results-in-Pancreatic-Cancer-from-Erasmus-University-Medical-Center-Rotterdam-Netherlands

    View Full Article Hide Full Article
  2. OCALA, FL / ACCESSWIRE / September 16, 2020 / AIM ImmunoTech Inc. (NYSE:AIM) today announced that recruitment has begun in Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19 infection, which is caused by the SARS-CoV-2 virus.

    Roswell Park has reported through the national clinical-trials database ClinicalTrials.gov that recruitment is underway for the study, which is led by two senior leaders at the Buffalo, N.Y., cancer center: Brahm Segal, MD, and Pawel Kalinski, MD, PhD.

    The study team describes their approach this way, as reported at ClinicalTrials.gov: "Interferon alpha is a protein…

    OCALA, FL / ACCESSWIRE / September 16, 2020 / AIM ImmunoTech Inc. (NYSE:AIM) today announced that recruitment has begun in Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19 infection, which is caused by the SARS-CoV-2 virus.

    Roswell Park has reported through the national clinical-trials database ClinicalTrials.gov that recruitment is underway for the study, which is led by two senior leaders at the Buffalo, N.Y., cancer center: Brahm Segal, MD, and Pawel Kalinski, MD, PhD.

    The study team describes their approach this way, as reported at ClinicalTrials.gov: "Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus."

    Approximately 6.4 million people in the United States have been infected with COVID-19 and more than 190,000 have died.

    "This trial reflects our ability to apply unique insights developed over the course of 20 years of work in cancer immunotherapy toward new strategies of engaging the innate immune system against virally mediated diseases," said Dr. Kalinski, scientific lead on the study and principal architect of this strategy as a treatment for both cancer and COVID-19. "Although this trial focuses on the treatment of patients infected with SARS-CoV-2, it is our hope that our findings may also have relevance for treatment of other RNA viruses, including such common pathogens as influenza, HIV and several oncogenic viruses."

    "Reducing replication of the virus may lead to less severe illness among patients at high risk for COVID-19 complications," added Dr. Segal, who is Chair of Internal Medicine and Chief of Infectious Diseases at Roswell Park, and clinical lead on this study.

    Funding for the Roswell Park clinical trial is provided, in part, through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park.

    For more information about this study, including eligibility criteria, please contact Roswell Park by phone at 1-800-ROSWELL (1-800-767-9355) or by e-mail to .

    About AIM ImmunoTech Inc.

    AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

    Contacts:

    Crescendo Communications, LLC
    Phone: 212-671-1021
    Email:

    AIM ImmunoTech Inc
    Phone: 800-778-4042
    Email:

    SOURCE: AIM ImmunoTech Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/606236/AIM-ImmunoTech-Highlights-Start-of-Recruitment-in-Roswell-Park-Clinical-Trial-Incorporating-Ampligen-in-the-Treatment-of-Cancer-Patients-with-Mild-or-Moderate-COVID-19

    View Full Article Hide Full Article
  3. OCALA, FL / ACCESSWIRE / September 10, 2020 / AIM ImmunoTech Inc. (NYSE:AIM) today announced that the company will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

    Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to present on Monday, September 14 at 5:00 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here.

    About AIM ImmunoTech Inc.

    AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

    Contacts:

    Crescendo…

    OCALA, FL / ACCESSWIRE / September 10, 2020 / AIM ImmunoTech Inc. (NYSE:AIM) today announced that the company will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.

    Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to present on Monday, September 14 at 5:00 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here.

    About AIM ImmunoTech Inc.

    AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

    Contacts:

    Crescendo Communications, LLC
    Phone: 212-671-1021
    Email:

    AIM ImmunoTech Inc
    Phone: 800-778-4042
    Email:

    SOURCE: AIM ImmunoTech Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/605463/AIM-ImmunoTech-to-Present-at-the-HC-Wainwright-22nd-Annual-Global-Investment-Conference-on-September-14th

    View Full Article Hide Full Article
  4. VICTORIA, BC, Sept. 8, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATF) (FSE:TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, will participate on a virtual panel, entitled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at 1:00 p.m. ET.

    The virtual panel discussion will also include: Tom Equels, CEO of AIM ImmunoTech Inc. (NYSE:AIM); Dr. David Jin, CEO of Avalon GlobloCare Corp. (NASDAQ:AVCO); Jeff Wolf, CEO of Heat Biologics, Inc. (NASDAQ:HTBX) and Vered Caplan, CEO of Orgenesis Inc. (NASDAQ:ORGS).

    The event brings together executives from leading biopharmaceutical companies to discuss how their companies are helping address the COVID-19 pandemic. The panel will be moderated by broadcast journalist Christine Corrado of Proactive Investors. Investors interested in attending the event can register at: 

    https://zoom.us/webinar/register/8215990551540/WN_YFe8n6dQSm6mpgG3iWfF-w

    About ImmunoPrecise Antibodies Ltd.

    ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company's experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise's full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact .

    Forward Looking Information

    This news release contains statements that, to the extent they are not recitations of historical fact, may constitute "forward-looking statements" within the meaning of applicable Canadian securities laws. The Company uses words such as "may", "would", "could", "will", "likely", "expect", "believe", "intend", "should" and similar expressions to identify forward-looking statements and include the Company's beliefs with respect to the potential for its antibodies to be further developed or approved to treat COVID-19 (or SARS-CoV-2) or to complete any transactions with respect to those antibodies. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise's expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise's actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise's annual management discussion and analysis for the previous quarter ended January 31, 2020 which can be accessed at www.sedar.com. The "forward-looking statements" contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    SOURCE ImmunoPrecise Antibodies Ltd.

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2020/08/c1782.html

    View Full Article Hide Full Article
  5. OCALA, FL / ACCESSWIRE / September 8, 2020 / AIM ImmunoTech Inc. (NYSE:AIM), today announced that Thomas K. Equels, CEO of AIM ImmunoTech, will participate in a virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at 1:00 p.m. ET.

    The virtual panel discussion will also include: Dr. David Jin, President and CEO of Avalon Globlocare Corp. (NASDAQ:AVCO); Jeff Wolf, CEO of Heat Biologics, Inc. (NASDAQ:HTBX); Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd. (TSXV:IPA) (OTCQB:IPATF) (FSE:TQB2); and Vered Caplan, CEO of Orgenesis Inc. (NASDAQ:ORGS).

    The event brings together executives from leading biopharmaceutical companies to discuss how their companies are helping address the…

    OCALA, FL / ACCESSWIRE / September 8, 2020 / AIM ImmunoTech Inc. (NYSE:AIM), today announced that Thomas K. Equels, CEO of AIM ImmunoTech, will participate in a virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at 1:00 p.m. ET.

    The virtual panel discussion will also include: Dr. David Jin, President and CEO of Avalon Globlocare Corp. (NASDAQ:AVCO); Jeff Wolf, CEO of Heat Biologics, Inc. (NASDAQ:HTBX); Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies Ltd. (TSXV:IPA) (OTCQB:IPATF) (FSE:TQB2); and Vered Caplan, CEO of Orgenesis Inc. (NASDAQ:ORGS).

    The event brings together executives from leading biopharmaceutical companies to discuss how their companies are helping address the COVID-19 pandemic. The panel will be moderated by broadcast journalist Christine Corrado of Proactive Investors. Investors interested in attending the event can register at: https://zoom.us/webinar/register/8215990551540/WN_YFe8n6dQSm6mpgG3iWfF-w.

    About AIM ImmunoTech Inc.

    AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

    Contacts:

    Crescendo Communications, LLC
    Phone: 212-671-1021
    Email:

    AIM ImmunoTech Inc
    Phone: 800-778-4042
    Email:

    SOURCE: AIM ImmunoTech Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/604807/AIM-ImmunoTech-CEO-to-Participate-in-Virtual-Panel-New-Approaches-to-COVID-19-Hidden-Breakthroughs-on-Thursday-September-10th

    View Full Article Hide Full Article
View All AIM ImmunoTech Inc. News